Emrullah Yilmaz

Emrullah Yilmaz

Hematology | Oncology

9500 Euclid Avenue
Cleveland, OH 44195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy.

Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy.

Journal: Oral oncology reports

Published: May 13, 2026

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 08, 2026

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 21, 2026

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.

Journal: Oral oncology

Published: October 09, 2025

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 19, 2025

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

Journal: Cancer

Published: November 08, 2024

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2024

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 04, 2024

Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges.

Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges.

Journal: JCO oncology practice

Published: May 06, 2024

Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.

Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.

Journal: Cancers

Published: January 26, 2024

Imaging Extranodal Extension (iENE) Predicts Higher Rates of Distant Recurrence for Human Papillomavirus-Positive Oropharyngeal Cancer.

Imaging Extranodal Extension (iENE) Predicts Higher Rates of Distant Recurrence for Human Papillomavirus-Positive Oropharyngeal Cancer.

Journal: International journal of radiation oncology, biology, physics

Published: November 23, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026